Gemox versus surveillance following surgery of localized biliary tract cancer: Results of the PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial.
Julien Edeline(Inserm), Éveline Boucher(Boston Scientific (United States)), Méher Ben Abdelghani(Université Paris Cité), Karine Bouhier‐Leporrier(Université Paris Cité), J. Watelet(Centre Hospitalier Régional et Universitaire de Nancy), David Malka(Inserm), Olivier Rosmorduc(Assistance Publique – Hôpitaux de Paris), Trevor Stanbury(UniCancer Group), Eric Assénat, Jean‐Paul Joly, Jean–Marc Phelip(Centre Hospitalier Universitaire de Saint-Étienne), Franck Bonnetain(Azienda Ospedaliera Universitaria Pisana), Pascal Hammel(Hôpital Paul-Brousse), Béata Juzyna(UniCancer Group), Aurélie Bertaut(Institut de Cancérologie de Bourgogne), Jean–Louis Jouve(Maison des Sciences sociales et des Humanités de Dijon), Véronique Guérin Meyer, Christophe Louvet(Institute Mutualiste Montsouris), Jean François Seitz(Canadian Partnership Against Cancer), Roger Faroux(Roche (Switzerland))
Cited by 110
Related Papers
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.9k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203
|Journal of Clinical Oncology|2006|1.7k